Boston Scientific Shares (Diluted) increased by 298900.0% to 1.5B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.1%, from 1.5B to 1.5B. Over 4 years (FY 2021 to FY 2025), Shares (Diluted) shows relatively stable performance with a 1.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase indicates potential dilution from employee compensation or convertible instruments, which can reduce earnings per share.
The weighted-average number of common shares outstanding plus the effect of all potentially dilutive securities, such as...
Standard metric for all public companies; essential for understanding the impact of equity-based compensation.
weighted_shares_diluted| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 1.4B | 1.4B | 800K | 1.4B | 1.4B | 1.4B | 1M | 1.4B | 1.5B | 1.5B | 4.4M | 1.5B | 1.5B | 1.5B | 1.4M | 1.5B | 1.5B | 1.5B | 500K | 1.5B |
| QoQ Change | — | +0.2% | -99.9% | >999% | -0.0% | +0.2% | -99.9% | >999% | +0.7% | +1.3% | -99.7% | >999% | +0.2% | +0.2% | -99.9% | >999% | +0.0% | +0.1% | -100.0% | >999% |
| YoY Change | — | — | — | — | +0.4% | +0.3% | +25.0% | +0.5% | +1.3% | +2.4% | +340.0% | +2.5% | +1.9% | +0.8% | -68.2% | +0.8% | +0.6% | +0.5% | -64.3% | +0.1% |